Nimorazole companion diagnostic - Azanta
Latest Information Update: 29 Sep 2020
At a glance
- Originator University of Aarhus
- Developer Azanta; European Organisation for Research and Treatment of Cancer; The Christie NHS Foundation Trust; University of Aarhus
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Head and neck cancer
Most Recent Events
- 29 Sep 2020 Nimorazole companion diagnostic is still in phase III trials for Head and Neck cancer (Diagnosis) in Switzerland, Netherlands, Germany and Australia (NCT01880359)
- 16 Jul 2020 Azanta in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) and Danish Head and Neck Cancer group completes a phase III trial in Head and neck cancer (Combination therapy, Diagnosis, First-line therapy, Late-stage disease) in Australia, Belgium, France, Germany, Netherlands and Switzerland (NCT01880359)
- 24 Mar 2020 Azanta has been acquired by Norgine